Detailed Information on Publication Record
2018
Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer
GUMULEC, Jaromír, Martina RAUDENSKÁ, Dalibor PACÍK, Mariana PLEVOVÁ, Alena SOROKAČ KUBOLKOVÁ et. al.Basic information
Original name
Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer
Authors
GUMULEC, Jaromír (203 Czech Republic, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Dalibor PACÍK (203 Czech Republic, belonging to the institution), Mariana PLEVOVÁ (703 Slovakia, belonging to the institution), Alena SOROKAČ KUBOLKOVÁ (703 Slovakia, belonging to the institution), Zuzana LACKOVÁ (203 Czech Republic), Natalia Vladimirovna CERNEI (498 Republic of Moldova), Vladislav STRMISKA (203 Czech Republic), Ondrej ZITKA (203 Czech Republic), Zbynek HEGER (203 Czech Republic) and Vojtech ADAM (203 Czech Republic, guarantor)
Edition
Cancer Medicine, Houston, John Wiley & Sons Ltd. 2018, 2045-7634
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.357
RIV identification code
RIV/00216224:14110/18:00104807
Organization unit
Faculty of Medicine
UT WoS
000450673300009
Keywords in English
outcome; prostate cancer; relapse; sarcosine; survival
Tags
International impact, Reviewed
Změněno: 10/2/2019 17:36, Soňa Böhmová
Abstract
V originále
To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post-treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow-up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post-treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (>= 200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine >= 200 vs <= 30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (>= 2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29-11.7) for sarcosine >200 vs <30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06-10.18), where (single) relapse-free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05-3.66). Urinary sarcosine may become a possible predictor for patients' outcomes, because patients with elevated post-treatment sarcosine could be predicted to have recurrent relapses of the disease.
Links
| ROZV/25/LF/2017, interní kód MU |
|